Peer-reviewed veterinary case report
Survival outcomes in dogs with joint versus other histiocytic sarcoma
By Klahn, Shawna L et al.·Published in Journal of the American Veterinary Medical Association·2011·Department of Small Animal Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation and comparison of outcomes in dogs with periarticular and nonperiarticular histiocytic sarcoma.
- Species:
- dog
Plain-English summary
A group of dogs with a type of cancer called periarticular histiocytic sarcoma (PAHS) was studied to see how their treatment outcomes compared to dogs with histiocytic sarcoma in other areas. The dogs with PAHS lived longer overall, with some living up to 980 days after treatment, even if they had signs of cancer spread at diagnosis. However, those with metastasis had shorter survival times. It was also found that giving prednisone, a common steroid, might actually worsen the outcome for these dogs. Treatments like chemotherapy or a combination of therapies seemed to help improve survival for dogs with PAHS.
People also search for: dog histiocytic sarcoma treatment · periarticular histiocytic sarcoma prognosis · prednisone effects on dog cancer
Abstract
OBJECTIVE: To evaluate and compare the outcomes of dogs with periarticular histiocytic sarcoma (PAHS) and histiocytic sarcoma of other anatomic locations (non-PAHS) and identify factors associated with outcome for dogs with PAHS. DESIGN: Retrospective cohort study. ANIMALS: 19 dogs with PAHS and 31 dogs with non-PAHS. PROCEDURES: Medical records of dogs with histiocytic sarcoma that underwent definitive local treatment (surgery or radiation), chemotherapy, or a combination of these were reviewed. Patient signalment, clinical signs, staging test results, clinicopathologic data, type of treatment, response, and outcome were collected, and potential risk factors in dogs with PAHS were identified and analyzed for an association with outcome. RESULTS: Dogs with PAHS lived significantly longer than did dogs with non-PAHS, with an overall median survival times of 391 (range, 48 to 980) and 128 (range, 14 to 918) days, respectively, despite the presence of suspected metastasis at diagnosis in 13 of 19 dogs with PAHS. Dogs with PAHS without evidence of metastasis at diagnosis lived significantly longer than did dogs with PAHS with evidence of metastasis, with median survival times of 980 (range, 83 to 980) and 253 (range, 48 to 441) days, respectively. Administration of prednisone in dogs with PAHS was associated with a significantly shorter time to tumor progression (TTP) and increased risk of tumor progression and death. CONCLUSIONS AND CLINICAL RELEVANCE: Results indicated that dogs with PAHS may have a favorable outcome independent of metastatic status when treated with chemotherapy or aggressive multimodal treatment. The concurrent administration of prednisone may be a negative predictive factor for survival time and TTP in dogs with PAHS.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/21718201/